Executives at biotechnology company Genzyme are disputing moneying a medical trial for a brand-new variation of a medical gadget called Synvisc. The trial is costly and the probabilities of success are low, however the benefit is considerable.
The case provides a typical company concern: invest or not? The case forces students to battle with a variety of intricate problems and examine the financials of their choices.
PUBLICATION DATE: January 26, 2010 PRODUCT #: KEL439-PDF-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
Related Case Solutions & Analyses:
Airwide International-China (A) Key Account Selling
Revenue Recognition and Multiple Deliverables: Disentangling Revenue Streams at Fluidigm
The Promises and Constraints of Consumer-Directed Healthcare
Info-Tech Research Group
Earnings Per Share
International Business Machines Corp. (C)
BayBank Boston
PSA Peugeot Citroen and world automobile branch
Laura Martin: Real Options and the Cable Industry
Buffett’s Bid for Media General’s Newspapers
